New pill hopes to calm Crohn's Flare-Ups
NCT ID NCT07403968
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called zasocitinib (TAK-279) in 20 adults with active Crohn's disease who have not responded to other treatments. The main goal is to see if the drug is safe and how it affects inflammation in the gut. Participants will take the drug for 12 weeks and undergo a colonoscopy to check for changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••